Clinical trials: Eczema/Atopic Dermatitis
Atopic Dermatitis
A Phase I Clinical Study to Evaluate SM17 in Chinese Healthy Subjects and Patients With Moderate to Severe Atopic Dermatitis
This trial is a phase 1, randomized, double-blind, placebo-controlled trial conducted in Chinese Healthy Volunteers and Patients with moderate-to-severe Atopic Dermatitis It aims to evaluate the safety, tolerability…
- Trial name
- NCT07103369
- Testing
- SM17 for injection
- Where
- China
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- SinoMab BioScience Ltd
Atopic Dermatitis
A Study to Evaluate the Safety and Efficacy of PAC-14028 Cream in Atopic Dermatitis
The study is a Phase II, single center, randomized, open-label, placebo-controlled study in male and female subjects, aged ≥ 20 years with mild to moderate atopic dermatitis.
- Trial name
- NCT02583022
- Testing
- PAC-14028 cream 1.0%, PAC-14028 cream vehicle, Elidel cream 1%
- Volunteers
- 74 people
- Sponsor
- Amorepacific Corporation
Atopic Dermatitis
Dupilumab Skin Barrier Function Study in Atopic Dermatitis
Primary Objective: Evaluate changes in skin barrier function with transepidermal water loss (TEWL) assessed after skin tape stripping (STS) in pre-defined lesional skin in participants with moderate to severe atopic dermatitis…
- Trial name
- BALISTAD (NCT04447417)
- Testing
- Dupilumab SAR231893
- Where
- 2 sites in United States, Canada
- Volunteers
- 52 people, healthy volunteers welcome
- Sponsor
- Sanofi
Atopic Dermatitis
Correlation Study Between PEST and SCORAD in Management of Atopic Dermatitis With Ceradan® Regimen
This is a prospective, open label, single arm, and observational and multicenter study to assess the correlation between PEST and SCORAD scores in the management of AD with the Ceradan® regimen.
- Trial name
- COPES (NCT02073591)
- Testing
- Ceradan Cream, Ceradan Wash
- Where
- 2 sites in Singapore
- Volunteers
- 58 people
- Sponsor
- Hyphens Pharma Pte Ltd
Atopic Dermatitis
A Study of the Long-Term Safety of Crisaborole Ointment, 2% in Japanese Pediatric and Adult Participants With Mild to Moderate Atopic Dermatitis
This study is a Phase 3, multicenter, open-label, long-term safety extension study of Studies C3291032 and C3291031 in Japanese pediatric and adult participants with mild to moderate Atopic Dermatitis (AD).
- Trial name
- NCT04498403
- Testing
- Crisaborole 2%
- Where
- 11 sites in Japan
- Volunteers
- 40 people
- Sponsor
- Pfizer
Moderate-to-Severe Atopic Dermatitis
A Study to Evaluate the Efficacy and Safety of AK139 in Patients With Moderate-to-severe Atopic Dermatitis
This is a randomized, double-blind phase II clinical study to evaluate the efficacy and safety of AK139 in the treatment of patients with moderate-to-severe atopic dermatitis.
- Trial name
- NCT07502222
- Testing
- AK139
- Volunteers
- 168 people
- Sponsor
- Akeso
Pruritus, Atopic Dermatitis
Phase IIa Safety and Efficacy Study of SRD174 Cream in Patients With AD-associated Pruritus
Pruritus is an essential feature for the diagnosis of atopic dermatitis and may play an important part in disease progression. Itching has a significant impact on the quality of life of AD sufferers, in particular night-time…
- Trial name
- NCT00838708
- Testing
- SRD174 Cream, vehicle cream
- Where
- 13 sites in United States
- Volunteers
- 62 people
- Sponsor
- Serentis Ltd.
Atopic Dermatitis
A Study to Assess Treat-to-Target and Dosing Flexibility of Oral Upadacitinib Tablets in Adult Participants With Moderate to Severe Atopic Dermatitis
Atopic dermatitis (AD) is a skin condition that may cause a rash and itching due to inflammation of the skin. Therapies spread over the skin may not be enough to control the AD in trial participants who require systemic…
- Trial name
- Flex-Up (NCT05507580)
- Testing
- Upadacitinib
- Where
- 106 sites in Australia, Belgium and 16 more
- Volunteers
- 461 people
- Sponsor
- AbbVie
Atopic Dermatitis
Phase 2a Study of the Safety, Tolerability, and Pharmacokinetics of Topically Administered PRN473 (SAR444727) in Patients With Mild to Moderate Atopic Dermatitis
This was a Ph2a study that consists of a double-blind, intra-patient placebo-controlled treatment period and an open-label uncontrolled treatment period with objective to evaluate the safety, tolerability, PK and preliminary…
- Trial name
- NCT04992546
- Testing
- PRN473 (SAR444727)
- Where
- 12 sites in United States, Canada
- Volunteers
- 39 people
- Sponsor
- Principia Biopharma, a Sanofi Company
Atopic Dermatitis
To Evaluate the Phase III Clinical Trial of TQH2722 Injection in the Treatment of Moderate to Severe Atopic Dermatitis
This is a randomized, double-blind, placebo-controlled clinical trial with 500 participants. In this study, the safety evaluation used the common toxic reaction criteria of the National Cancer Institute to evaluate the adverse…
- Trial name
- NCT06552520
- Testing
- TQH2722 injection
- Where
- 73 sites in China
- Volunteers
- 500 people
- Sponsor
- Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.
Safety Issues
A Phase I Clinical Study of Hemay808
This is a first-in-human study in health volunteers. The purpose is the local tolerability and systemic safety of Hemay808, which is an ointment made of a novel small molecule Hemay028.
- Trial name
- NCT04100642
- Testing
- Hemay808
- Where
- China
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- Tianjin Hemay Pharmaceutical Co., Ltd
Atopic Dermatitis
Comparison Trial of OPA-15406 Ointment in Adult Patients With Atopic DermatitisSyndrome
To demonstrate the superiority of IMP (1% OPA-15406 ointment or vehicle) to the vehicle when administered twice daily for 4 weeks using success rate in Investigator's Global Assessment (IGA) at Week 4 as the primary endpoint in…
- Trial name
- NCT03908970
- Testing
- 1% OPA-15406
- Where
- Japan
- Volunteers
- 364 people
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
Atopic Dermatitis
Study of CM310 Injection in Subjects With Moderate-to-Severe Atopic Dermatitis
This study is a multi-center, randomized, double-blind, parallel controlled phase 2 study, aimed at evaluating the efficacy and safety of CM310 in the treatment of patients with moderate-to-severe atopic dermatitis, and observing…
- Trial name
- NCT05715320
- Testing
- CM310
- Where
- China
- Volunteers
- 160 people
- Sponsor
- Keymed Biosciences Co.Ltd
Atopic Dermatitis
Efficacy Emollient on Xerosis in Children With Atopic Dermatitis
Atopic dermatitis is a frequent, chronic inflammatory disease influenced by local, immunological, genetic and environmental factors.
- Trial name
- NCT01467362
- Testing
- V0034CR01B, Vehicle cream, desonide 0.1% cream
- Where
- 25 sites in Estonia, France and 3 more
- Volunteers
- 251 people
- Sponsor
- Pierre Fabre Medicament
Dermatitis, Atopic, Pruritus
Study to Evaluate ASN008 Topical Gel (TG)
This is an ascending dose escalation study to test the safety, tolerability and preliminary efficacy of ASN008 TG in first-in-human subjects
- Conditions
- Dermatitis, Atopic, Pruritus, Dermatitis Eczema
- Trial name
- NCT03798561
- Testing
- ASN008 TG
- Where
- 5 sites in United States, Canada
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Asana BioSciences
Pregnancy Related, Atopic Dermatitis
Study to Compare Maternal, Fetal, and Infant Outcomes of Women With Mild to Moderate Atopic Dermatitis Exposed to Ruxolitinib Cream During Pregnancy With an Unexposed Control Population
This observational (enrollment into the registry while the pregnancy is ongoing) study is being conducted to compare the frequency of major congenital malformation (MCM)s among infants of women exposed to ruxolitinib cream during…
- Trial name
- OPERA-1 (NCT06259669)
- Testing
- Ruxolitinib Cream
- Where
- United States
- Volunteers
- 958 people
- Sponsor
- Incyte Corporation
Atopic Dermatitis
Description of the Population With Moderate to Severe Atopic Dermatitis, Treated by Systemic Treatments and Needs Regarding Emollients
Atopic dermatitis (AD) is a common chronic inflammatory skin disease, affecting both children (15- 20%) and adults (2-5%). The pathogenesis of AD is complex and multifactorial, including skin barrier dysfunction and immune…
- Trial name
- NCT06983561
- Where
- France
- Volunteers
- 80 people
- Sponsor
- Pierre Fabre Dermo Cosmetique
Atopic Dermatitis
French Prospective Observational Study in Patients Eligible for Systemic Therapy for Atopic Dermatitis (AD)
The objective of the study is to describe the therapeutic management of patients more than or equal to 18 years old eligible for systemic therapy or treated by systemic therapy for atopic dermatitis (AD).
- Trial name
- FRAME (NCT06837454)
- Where
- 61 sites in France
- Volunteers
- 600 people
- Sponsor
- Sanofi
Atopic Dermatitis (AD), Eczema
Efficacy Study of EVO301 in Moderate to Severe Atopic Dermatitis
This is a Phase 2a efficacy and safety study of EVO301 for the treatment of adults with atopic dermatitis.
- Conditions
- Atopic Dermatitis (AD), Eczema, Eczema Atopic Dermatitis
- Trial name
- NCT06723405
- Testing
- EVO301
- Where
- 12 sites in Australia, New Zealand
- Volunteers
- 71 people
- Sponsor
- Evommune, Inc.
Eczema
Alitretinoin in the Treatment of Chronic Hand Eczema
The purpose of the study is to investigate the safety and efficacy of alitretinoin in chronic hand eczema that is refractory to topical corticosteroids.
- Trial name
- NCT00519675
- Testing
- alitretinoin
- Where
- 4 sites in France, Germany
- Volunteers
- 150 people
- Sponsor
- Basilea Pharmaceutica
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.